Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Dec 31, 2025
Reporting period
Not applicable
Filed with the SEC
Jan 5, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001679166-26-000002
Filed / recorded
Jan 5, 2026, 10:35 PM UTC
Added to OQRO
Oct 6, 2026, 7:37 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Elanco Animal Health Inc
Issuer CIK
1739104
Ticker
ELAN
Reporting person
Kapila K Anand
Relationship
Director
Security
Deferred Stock Units
Table
Derivative (Table II)
Transaction date
Dec 31, 2025
Transaction code
A
Shares / units
381.1312
Price per share
$22.63
Acquired / disposed
Acquired (A)
Shares owned after
8,894.7414
Ownership form
Direct
Amendment
No
Footnotes from the filing
Ms. Anand elected to defer her director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock.
The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan.
The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $22.63 on December 31, 2025.
